Myungji Building, 142-21 Samsung-dong
105 articles with Seegene, Inc.
Seegene Inc., a leading biotechnology firm specializing in molecular diagnostics, is unveiling a fully automated PCR testing system at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo to be held on September 26-30, 2021, in Atlanta, GA, USA.
Seegene Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four COVID-19 Diagnostic Tests
Seegene Inc., South Korea's leading molecular diagnostics company, announced on August 20 that it has obtained CE marking for the use of Combo Swab, a self-collection device with four diagnostic assays.
Seegene Inc., a leading biotechnology company specializing in molecular diagnostics, announced financial results for the second quarter ended June 30, 2021.
Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus
South Korea's leading biotechnology firm Seegene Inc. has announced the launch of a new SARS-CoV-2 variant diagnostic test capable of screening newly emerging virus variants including the Delta and the Delta Plus that have become the dominant version of the virus circulating around the world.
Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market
Seegene announced on July 1 that it has signed a partnership with Bio-Rad, laboratories, Inc. for the clinical development and commercialization of infectious disease molecular diagnostic products.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products.
Seegene unveils "MOBILE STATION," for on-site routine testing at public-use facilities and communities
South Korea's leading biotechnology firm Seegene Inc. introduced its new deployable container laboratory "MOBILE STATION", at the Medlab Middle East 2021, the world's largest medical laboratory and In Vitro Diagnostic exhibition which is taking place in Dubai from June 21 to 24.
Seegene Inc., a biotechnology firm specializing in molecular diagnostics has once again been recognized for its unique system for diagnosing COVID-19 variants at this year's European Congress of Clinical Microbiology, the ECCMID.
We are advised by Seegene Inc. that journalists and other readers should disregard the news release, Seegene reports solid results in the first quarter of 2021 with KRW 351.8 billion , issued 11-May-2021 over PR Newswire. SOURCE Seegene Inc.
Seegene Inc., South Korea's largest molecular diagnostics firm, will be supplying COVID-19 diagnostic kits worth over $4.8 million to the Kuwaiti government.
Seegene Inc., a molecular diagnostics company reported its financial results for the first quarter of 2021, with reports showing robust earnings.
Seegene Inc., a leading molecular diagnostics firm said its German subsidiary, Seegene Germany GmbH is taking part in the government's Back-to-School program called the "Lolli-Test," a starting point in returning our daily lives back to normalcy.
Seegene to supply COVID-19 diagnostic tests worth 16 mil. GBP to Scotland, triple the sales volume seen last year
Seegene Inc. (KQ 096530), a leading biotechnology firm said it began supplying its COVID-19 diagnostic tests worth 16,209,150 GBP to Scotland under a public procurement agreement, the largest diagnostic volume seen in that r
Seegene's Italy subsidiary secures public procurement for 7.15 million COVID-19 diagnostic tests, the largest tender in history
Seegene Inc., a leading molecular diagnostics firm said its Italian subsidiary, the Arrow Diagnostics Srl, has secured the public procurement worth over EUR 89.3 million, the largest volume of tender in the history of its Italian branch since 2014.
Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic
Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month
South Korea's leading molecular diagnostics firm Seegene Inc. reported preliminary financial results for the fourth quarter and the fiscal year of 2020, showing records never seen before.
A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen.
South Korea's biotechnology firm Seegene said Monday it developed the world's first COVID-19 diagnostic variant test, capable of screening COVID-19 and identifying multiple mutant variations in a single reaction.
South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. said Tuesday that it has CE-IVD marked the saliva-based testing application for Allplex™ SARS-CoV-2 Assay and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, and that the products with the feature are now available in Europe.
Seegene's aggregated sales surpass KRW 1 tril. this year and plans on expanding annual production capacity to KRW 5 tril. in 2021
South Korea's biotechnology company specializing in molecular diagnosis, Seegene Inc., announced Monday that its aggregated sales this year have already surpassed the KRW 1 trillion mark, up nearly 10 times its previous annual sales of KRW 120 billion in 2019.